Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of subcutaneous amlitelimab in moderate to severe atopic dermatitis
jRCT2031220522Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Open-label trial of amlitelimab in atopic dermatitis (AD) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of participants who experienced treatment-emergent adverse event. Started Jan 2023; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031220522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220522.